Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.

Abstract

Based on RESTORE 1-year follow-up data, ranibizumab monotherapy appears to be cost-effective relative to laser monotherapy, the current standard of care. Cost-effectiveness of combination therapy is less certain.

Ongoing studies will further inform on disease progression and the need for additional ranibizumab treatment.

Full Text

• DOI - The British journal of ophthalmology (DOI)
• UK PubMed Central - full-text online
• PubMed Central - full-text online
• Ovid Technologies, Inc. - full-text online
• Lippincott Williams & Wilkins - full-text online
• HighWire Press - full-text online
• HighWire Press - full-text online
• EBSCO - full-text online
• PubMed Central Canada - full-text online

Subjects

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Combined Modality Therapy
• Cost-Benefit Analysis
• Diabetic Retinopathy
• Drug Costs
• Great Britain
• Humans
• Laser Coagulation
• Macular Edema
• Markov Chains
• Quality-Adjusted Life Years
• Vision Disorders
• Visual Acuity

Similar articles

• Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. (2007-08-21)
• The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration. (2013-03-20)
• The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. (2011-04-04)
• LUCEDEX: A Prospective Study Comparing Ranibizumab plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Neovascular Age-Related Macular Degeneration. (2013-03-30)
• A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. (2012-09-17)
• A cost-effectiveness analysis of three treatments for age-related macular degeneration. (2010-02-09)
• Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. (2013-03-30)
• Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (2012-08-03)
• The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. (2007-09-26)

Authors

• Paul Mitchell
• Lieven Annemans
• Meghan Gallagher
• Rafiq Hasan
• Simu Thomas
• Kerry Gairy
• Martin Knudsen
• Henrietta Onwordi

Publication date

2012-04-17

Journal

Journal topics

• Ophthalmology

Language

Eng.

Copyright

The British journal of ophthalmology

Centre for Vision Research, Westmead Millennium Institute, Westmead Hospital, Hawkesbury Rd, Westmead, 2145 Australia. paul.mitchell [at] sydney.edu.au

Release reference

Br J Ophthalmol. 2012 May;96(5):688-93

Related books

• Books of Angiogenesis Inhibitors
• Books of Antibodies, Monoclonal, Humanized
• Books of Combined Modality Therapy
• Books of Cost-Benefit Analysis
• Books of Diabetic Retinopathy
• Books of Drug Costs
• Books of Great Britain
• Books of Laser Coagulation
• Books of Macular Edema
• Books of Markov Chains
• Books of Ophthalmology
• Books of Quality-Adjusted Life Years
• Books of Vision Disorders
• Books of Visual Acuity